Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Most linked-to pages

From GxPlex

Jump to: navigation, search

Showing below up to 50 results in range #351 to #400.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Reference:GBR Guidance Managing clinical trials during Coronavirus (COVID-19) 16-Nov-.2021 - (7 links)
  2. Reference:GBR HRA - Ending your project 28-Jan-2025 - (7 links)
  3. Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 4 (7 links)
  4. Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 5 - 6 (7 links)
  5. Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 7.1 (7 links)
  6. Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 7.2 (7 links)
  7. Reference:GBR Making changes to a research study to manage the impact of COVID-19 12-Oct-2021 - (7 links)
  8. Reference:GBR The Medical Devices Regulations 2002 11-Feb-2021 Article 16 (11) (7 links)
  9. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 27 (7 links)
  10. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 29A (7 links)
  11. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 2 serious adverse event (7 links)
  12. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 30-001 (7 links)
  13. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 30-002 (7 links)
  14. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 31 (7 links)
  15. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 1 Part 2 12. (7 links)
  16. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 3 Part 1 1. (i) (7 links)
  17. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 3 Part 1 1. (p) (7 links)
  18. Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 5 (5) (7 links)
  19. Reference:ICH ICH E11 Guideline R1 (2017) 8 (7 links)
  20. Reference:ICH ICH E2A Guideline 1994 III A. 1. (7 links)
  21. Reference:ICH ICH E2A Guideline 1994 III B. - III C. (7 links)
  22. Reference:ICH ICH E6 Guideline - Annex 2 R3 Annex 2 Annex 2 2.2 (7 links)
  23. Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 5 (7 links)
  24. Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 6-001 (7 links)
  25. Reference:ICH ICH E6 Guideline R3 (2025) Appendix B 6-002 (7 links)
  26. Reference:ICH ICH E6 Guideline R3 (2025) Appendix C 2 (7 links)
  27. Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Audit (7 links)
  28. Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Inspection (7 links)
  29. Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Source Records (7 links)
  30. Reference:ICH ICH E6 Guideline R3 (2025) GLOSSARY - Suspected Unexpected Serious Adverse Reaction (SUSAR) (7 links)
  31. Reference:ICH ICH E6 Guideline R3 (2025) II (7 links)
  32. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.10 (7 links)
  33. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.11 (7 links)
  34. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.12.10 (7 links)
  35. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.12.11 – 2.12.14 (7 links)
  36. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.12.5 – 2.12.9 (7 links)
  37. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.13 (7 links)
  38. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.4.2 (7 links)
  39. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.5 (7 links)
  40. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.7.1-002 (7 links)
  41. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.7.2 (a) - (d) (7 links)
  42. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 2.8.13 (7 links)
  43. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.11.2 (7 links)
  44. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.11.4.5.3 (7 links)
  45. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.11.4 3.11.4.1 - 3.11.4.2 (7 links)
  46. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.11.4 3.11.4.3 - 3.11.4.6 (7 links)
  47. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.12 (7 links)
  48. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.13.2 (a) - (b) ; (d) - (f) (7 links)
  49. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.13.2 (c) (7 links)
  50. Reference:ICH ICH E6 Guideline R3 (2025) III. Annex 1 3.14-001 (7 links)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://gxplex.org/index.php?title=Special:MostLinkedPages"